Covid: Talks on to make ZyCoV-D part of inoculation programme, says govt

Preparations are on to make Zydus Cadila's COVID-19 DNA vaccine available to people, a decision will be taken soon to make it a part of the country's vaccination programme

coronavirus, covid-19, vaccine, vaccination
Photo: Bloomberg
Press Trust of India New Delhi
2 min read Last Updated : Sep 23 2021 | 8:58 PM IST

Preparations are on to make Zydus Cadila's COVID-19 DNA vaccine available to people and although the price is a "clear issue", a decision will be taken soon to make it a part of the country's vaccination programme, the government said on Thursday.

Responding to a question at a press conference, NITI Aayog Member (Health) Dr V K Paul said to bring Zydus Cadila's DNA vaccine in practical shape and implementation, preparations are going on and repeated discussions have been held.

"The price is also a clear issue. Talks are going on and a decision will soon be taken. With full preparation, it will become a part of the country's national vaccination programme. We are looking forward to receiving recommendations of the NTAGI on the beneficiary or target group to which the vaccine has to be given. The work is in progress and you will hear more about this in the times to come," he said.

Paul also said the Covaxin results for children's vaccines are in final phases and expected soon. The results will be submitted to the drug regulator. Then the subject expert committee will look into it and once the regulator gives its approval, it can be used, he added.

Zydus Cadila's indigenously-developed needle-free COVID-19 vaccine ZyCoV-D received the Emergency Use Authorisation from the Drugs Controller General of India last month and will be administered to those aged 12 years and above.

With the Emergency Use Authorisation (EUA), ZyCoV-D became the first vaccine to be administered to those in the age group of 12-18 years in the country.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusZydus Cadila

First Published: Sep 23 2021 | 8:58 PM IST

Next Story